Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • ritarebollo
    Junior Member
    • Feb 2012
    • 2

    Comparing two ChIP-seq libraries

    Hello,

    I am new to ChIP-seq data mining (by myself) and I am having a hard time comparing two ChIP-seq data sets. Could you tell me if my pipeline is correct and if I should add a normalization step somewhere? I am simply going through this with each one of my IP-Input files and looking at the genome browser. The problem is the IP of sample B is sequenced at a bigger depth than sample A and it seems the peaks are not all being called. When I compare to previously published data it seems I am missing some peaks on sample B. I thought about changing some thresholds on sample B but then the pipeline would be different from sample A... So, what should I do to ensure all my peaks are present in sample B but the data is still comparable to sample A? Thanks!!!



    Samples : H3K4me3 and Input data on sample A and H3K4me3 and Input data on sample B.

    Original file : BAM (from the sequences).

    My pipeline :

    Sort pair-ended BAM files by read name
    samtools sort –n c3h.input.bam c3h.input.sorted

    Convert BAM files to FASTQ format
    bam2fastx -q -Q -A -o c3h.input.fastq -P -N c3h.input.sorted.bam

    Map reads to the genome
    bowtie2 –p 8 -x ~/Data/Genomes/mm10/bt2idx/bt2idx -1 c3h.input.1.fastq -2 c3h.input.2.fastq -S c3h.input.sam&

    Bowtie2 options:

    End-to-end alignment (default) vs. local alignment (--local)

    Paired-end alignment: -1 mate1.fq -2 mate2.fq

    Concordant + discordant alignment (default) vs. concordant only (--no-discordant)

    Mixed mode: paired where possible; otherwise unpaired (default) vs. paired-only mode (--no-mixed)

    Overlapping with the other mate is concordant (default) vs. (--no-overlap)

    Containing the other mate is concordant (default) vs. (--no-contain)

    Dovetailing the other mate is discordant (default) vs. (--dovetail)



    Bowtie2 output:

    Mapping quality: MAPQ

    Peak analysis using MACS2
    macs2 callpeak -t ~/Data/BCCRC/chipseq/mapping/tt2.k4m3.sam -c ~/Data/BCCRC/chipseq/mapping/tt2.input.sam -f SAM -g mm -n tt2.k4m3 -B -q 0.01 --outdir ~/Data/BCCRC/chipseq/tt2.k4m3.out



    MACS2 options:

    -g (genome size, mm=1.87e9)

    -B/-bdg (bedGraph format for pile-up files)

    -q (The qvalue (minimum FDR) cutoff to call significant regions)

    Thank you! I am a bit at lost as it has been already a couple of months we are trying to get this done...

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 11:41 AM
0 responses
9 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
35 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-09-2026, 10:04 AM
0 responses
45 views
0 reactions
Last Post SEQadmin2  
Working...